We report a case of a 36-year-old male that was diagnosed with acute promyelocytic leukemia and was treated with all-trans retinoid acid and idarrubicin. 9 days after ATRA introduction he developed a fever. He was started on broad-spectrum antibiotic and was extensively investigated for infectious diseases without confirmation of an infectious etiology. 24 days after ATRA introduction he complained of pain in his right calf. Physical examination showed redness, and swelling, doppler ultrasound was was negative for deep vein thrombosis. He underwent a magnetic resonance imaging scan that detected volumetric increase in medial and lateral gastrocnemius and edema; findings were suggestive of myositis. He was treated with ATRA withdrawal and dexamethasone with rapid improvement of his condition. A follow-up magnetic resonance imaging scan was done 7 days after corticotherapy and showed no signs of myositis. At the time of this writing he is receiving maintenance with 6-mercaptopurine, methotrexate and ATRA. He remains in remission and did not experience myositis recurrence. To the best of our knowledge, only 15 cases of ATRA-related myositis have been reported to date. This report highlights the importance of a rare but important ATRA side effect that, if not promptly recognized, can have a fatal course.
The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
© Clarivate Analytics, Journal Citation Reports 2025
SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.
See moreSNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.
See more